These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 29666149)
1. Genetic and phenotypic difference in CD8 Wang X; He Q; Shen H; Lu XJ; Sun B J Med Genet; 2019 Jan; 56(1):18-21. PubMed ID: 29666149 [TBL] [Abstract][Full Text] [Related]
2. PD1 Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783 [TBL] [Abstract][Full Text] [Related]
3. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8 Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359 [TBL] [Abstract][Full Text] [Related]
4. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1 Ye L; Zhang Q; Cheng Y; Chen X; Wang G; Shi M; Zhang T; Cao Y; Pan H; Zhang L; Wang G; Deng Y; Yang Y; Chen G J Immunother Cancer; 2018 Dec; 6(1):145. PubMed ID: 30526680 [TBL] [Abstract][Full Text] [Related]
5. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma. Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222 [TBL] [Abstract][Full Text] [Related]
6. T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. Wang YG; Zheng DH; Shi M; Xu XM J Med Genet; 2019 Jan; 56(1):22-28. PubMed ID: 30518547 [TBL] [Abstract][Full Text] [Related]
7. Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma. Shi J; Wang Y; Wang F; Zhu Z; Gao Y; Zhang Q; Du Z Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):855-864. PubMed ID: 32205116 [TBL] [Abstract][Full Text] [Related]
8. High expression of circulating exosomal PD-L1 contributes to immune escape of hepatocellular carcinoma and immune clearance of chronic hepatitis B. Lin X; Shao H; Tang Y; Wang Q; Yang Z; Wu H; Xing T Aging (Albany NY); 2024 Jul; 16(14):11373-11384. PubMed ID: 39028365 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size. Wang Q; Luan W; Warren L; Fiel MI; Blank S; Kadri H; Mandeli J; Hiotis SP J Immunother; 2016 Jan; 39(1):36-44. PubMed ID: 26641260 [TBL] [Abstract][Full Text] [Related]
10. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. Moreno-Cubero E; Larrubia JR World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-35 Suppresses Interleukin-9-Secreting CD4 Zhang Q; Yang L; Liu S; Zhang M; Jin Z Front Immunol; 2021; 12():645835. PubMed ID: 34177894 [TBL] [Abstract][Full Text] [Related]
12. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Kennedy PTF; Sandalova E; Jo J; Gill U; Ushiro-Lumb I; Tan AT; Naik S; Foster GR; Bertoletti A Gastroenterology; 2012 Sep; 143(3):637-645. PubMed ID: 22710188 [TBL] [Abstract][Full Text] [Related]
13. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336 [TBL] [Abstract][Full Text] [Related]
14. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208 [TBL] [Abstract][Full Text] [Related]
15. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124 [TBL] [Abstract][Full Text] [Related]
16. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Li FJ; Zhang Y; Jin GX; Yao L; Wu DQ Immunol Lett; 2013 Feb; 150(1-2):116-22. PubMed ID: 23261718 [TBL] [Abstract][Full Text] [Related]
17. HBV-Induced Immune Imbalance in the Development of HCC. Chen Y; Tian Z Front Immunol; 2019; 10():2048. PubMed ID: 31507621 [TBL] [Abstract][Full Text] [Related]
18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-35 Dampens CD8 Yang L; Shao X; Jia S; Zhang Q; Jin Z Front Immunol; 2019; 10():1032. PubMed ID: 31134088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]